Gagan Kukreja Shares A Study On Novel Neuroprotective Agents for Ischemic Stroke
Gagan Kukreja, Lead Medicinal Chemistry Strategist at Syngene International Limited, shared on LinkedIn:
”Holding promise as a treatment of Ischemic stroke (IS), an acute cerebrovascular condition, the publication describes a novel class of pyrazole carboxylic acid borneol esters as novel neuroprotective agents demonstrating potent scavenging activity against nitrogen/oxygen free radicals
With preliminary biosafety studies indicating no obvious organ toxicity, the identified candidate B16, not only restored cerebral blood flow and significantly reduces infarct size in middle cerebral artery occlusion/reperfusion (MCAO/R) mice, but also improved sensory and motor functions, and promotes the recovery of neuronal cells and the blood-brain barrier (BBB) in the brain.
Xueyang Jiang et al”
Read the full article here.
Article: Pyrazole carboxylic acid borneol esters: Novel neuroprotective agents with rapid, efficient brain penetration for the treatment of ischemic stroke
Authors: Siyi Li, Yulu Wu, Wang Chen, Peng Zhu, Xin Lu, Jiaming Li, Xiaodong Ma, Xueyang Jiang
Stay updated on all scientific advances with Hemostasis Today.
-
May 22, 2026, 15:02Robert Brodsky: Can You Stop Thrombosis and Treat CAPS Without Anticoagulation?
-
May 22, 2026, 14:50Eric Topol: New Nature Editorial on the Limits and Promise of AI Scientists
-
May 22, 2026, 14:40Harry Spoelstra: Omicron COVID-19 and Coronary Thrombosis Without Atherosclerosis
-
May 22, 2026, 14:21Clinical Challenges in Thrombosis III – Thrombosis Canada
-
May 22, 2026, 14:03Wolfgang Miesbach: Exploring the Role of Micronutrients in Healthy Longevity
-
May 22, 2026, 13:53Masoabi Sefojane: The Structural Invisibility of Bleeding Disorders in the Global South
-
May 22, 2026, 13:41Ney Carter Borges: New Trial Highlights IVL as Effective Strategy for Calcified Coronary Lesions
-
May 22, 2026, 13:36Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency